On April 30, 2010
Provenge, a New $93K Cancer Drug, Will Be Extremely Effective — on Taxpayers
Who will pay $93,000 for Provenge, Dendreon (DNDN)’s new vaccine-based treatment for advanced prostate cancer? The answer is you. And me. The taxpayer.
No tags for this post.
0 Comments